Cystadane
Peroxisome Biogenesis Disorders
McGill University Health Centre/Research Institute of the McGill University Health CentrePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Peroxisome Biogenesis Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CHOLALIC ACID Mirum Pharmaceuticals, Inc. | Phase 3 | B |
Hydroxychloroquine The Hospital for Sick Children | Phase 2 | B |
Cald Hr-D Masonic Cancer Center, University of Minnesota | Phase 2 | CCC |
Chenodeoxycholic Acid | N/A | D |
URSODEOXYCHOLIC ACID | N/A | D |
Same molecule, other indications
Cystadane is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →